Drew N. Wilfahrt

Drew N. Wilfahrt

Auto-generated profile, based on publicly available information

Drew N. Wilfahrt

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KDKristin DePeaux
Kristin DePeaux
DRDayana B. Rivadeneira
Dayana B. Rivadeneira
KLKonstantinos Lontos
Konstantinos Lontos
VDVictoria G. Dean
Victoria G. Dean
WGWilliam G. Gunn
William G. Gunn
GDGreg M. Delgoffe
Greg M. Delgoffe
While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments enhancing immune infiltration and preventing immunosuppression are of critical need. We previously generated αPD-1 resistant variants of the murine HNSCC model MEER. While entirely αPD-1 resistant, these tumors regress after single dose of oncolytic vaccinia virus (VV). We then generated a VV-resistant MEER line to dissect the immunologic features of sensitive and resistant tumors. While treatment of both tumor types induced immune infiltration and IFNγ, we found a defining feature of resistance was elevation of immunosuppressive cytokines like TGFβ, which blunted IFNγ signaling, especially in regulatory T cells. We engineered VV to express a genetically encoded TGFβRII inhibitor. Inhibitor-expressing VV produced regressions in resistant tumor models and showed impressive synergy with checkpoint blockade. Importantly, tumor-specific, viral delivery of TGFβ inhibition had no toxicities associated with systemic TGFβ/TGFβR inhibition. Our data suggest that aside from stimulating immune infiltration, oncolytic viruses are attractive means to deliver agents to limit immunosuppression in cancer.

30 July 2025 in Cancer Discovery
Verified
Journal Article
Open access
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Gut microbiota composition is directly associated with response to immunotherapies in cancer. The impact of diet on the gut microbiota and downstream immune responses to cancer remains unclear. In this study, we show that consumption of a common nonnutritive sweetener, sucralose, modifies microbiome composition, restricts T-cell metabolism and function, and limits immunotherapy response in preclinical models of cancer and patients with advanced cancer treated with anti–PD-1–based immune checkpoint inhibitors. Sucralose consumption is associated with a reduction in microbiota-accessible arginine, and amino acid supplementation or fecal microbiome transfer from anti–PD-1 responder mice completely restores T-cell function and immunotherapy response. Overall, sucralose consumption destabilizes the gut microbiota, resulting in compromised T-cell function and ablated immune checkpoint inhibitor response in cancer. Significance: This study highlights an unappreciated role of sucralose in reducing immunotherapy efficacy in both mouse models and samples from patients with cancer through shifts in the microbiome and arginine degradation that lead to T-cell exhaustion. T-cell function and immunotherapy responses are restored through amino acid supplementation. See related commentary by Chandra et al., p. 2196

19 August 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.

1 October 2025
Verified
Other
Open access
CACatarina M. Azevedo
Catarina M. Azevedo
BXBingxian Xie
Bingxian Xie
WGWilliam G. Gunn
William G. Gunn
RPRonal M. Peralta
Ronal M. Peralta
CDCarolina S. Dantas
Carolina S. Dantas
SPSalomé Pinho
Salomé Pinho
T-cell therapies have transformed cancer treatment. Although surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc–branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR-Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted the assessment of whether MGAT5 deletion in anti-CD19 chimeric antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 knockout anti-CD19–CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance the antitumor activity of native and CAR T cells.